Posted by Michael Wonder on 18 Oct 2016
CADTH calls for patient input on a submission for Zinbryta (daclizumab)
18 October 2016 - CADTH is calling for patient input on Biogen's submission for Zinbryta (daclizumab).
Biogen is seeking a favourable CADTH outcome for daclizumab for use by patients with relapsing multiple sclerosis.
The submission is due on 15 November 2016.
